The coronavirus disease of 2019 (COVID-19) has evolved into a worldwide pandemic. Although CT is sensitive in detecting lesions and assessing their severity, these works mainly depend on radiologists’ subjective judgment, which is inefficient in case of a large-scale outbreak. This work focuses on developing a CT-based radiomics model to assess whether COVID-19 patients are in the early, progressive, severe, or absorption stages of the disease. We retrospectively analyzed the CT images of 284 COVID-19 patients. All of the patients were divided into four groups (0-3): early ( ), progressive ( ), severe ( ), and absorption ( ) groups, according to the progression of the disease and the CT features. Meanwhile, they were split randomly to training and test datasets with the fixed ratio of 7 : 3 in each category. Thirty-eight radiomic features were nominated from 1688 radiomic features after using select -best method and the ElasticNet algorithm. On this basis, a support vector machine (SVM) classifier was trained to build this model. Receiver operating characteristic (ROC) curves were generated to determine the diagnostic performance of various models. The precision, recall, and -score of the classification model of macro- and microaverage were 0.82, 0.82, 0.81, 0.81, 0.81, and 0.81 for the training dataset and 0.75, 0.73, 0.73, 0.72, 0.72, and 0.72 for the test dataset. The AUCs for groups 0, 1, 2, and 3 on the training dataset were 0.99, 0.97, 0.96, and 0.93, and the microaverage AUC was 0.97 with a macroaverage AUC of 0.97. On the test dataset, AUCs for each group were 0.97, 0.86, 0.83, and 0.89 and the microaverage AUC was 0.89 with a macroaverage AUC of 0.90. The CT-based radiomics model proved efficacious in assessing the severity of COVID-19.
1 February 2025 in Diabetes, Metabolic Syndrome and Obesity
Purpose: To explore the potential of MRI-based radiomics in predicting cognitive dysfunction in patients with diagnosed type 2 diabetes mellitus (T2DM). Patients and Methods: In this study, data on 158 patients with T2DM were retrospectively collected between September 2019 and December 2020. The participants were categorized into a normal cognitive function (N) group (n=30), a mild cognitive impairment (MCI) group (n=90), and a dementia (DM) group (n=38) according to the Chinese version of the Montréal Cognitive Assessment Scale-B (MoCA-B). Radiomics features were extracted from the brain tissue except ventricles and sulci in the 3D T1WI images, support vector machine (SVM) model was then established to identify the CI and N groups, and the MCI and DM groups, respectively. The models were evaluated based on their area under the receiver operating characteristic curve (AUC), Precision (P), Recall rate (Recall, R), F1-score, and Support. Finally, ROC curves were plotted for each model. Results: The study consisted of 68 cases in the N and CI group, with 54 cases in the training set and 14 in the verification set, and 128 cases were included in the MCI and DM groups, with 90 training sets and 38 verification sets. The consistency for inter-group and intra-group of radiomics features in two physicians were 0.86 and 0.90, respectively. After features selection, there were 11 optimal features to distinguish N and CI and 12 optimal features to MCI and DM. In the test set, the AUC for the SVM classifier was 0.857 and the accuracy was 0.830 in distinguishing CI and N, while AUC was 0.821 and the accuracy was 0.830 in distinguishing MCI and DM. Conclusion: The SVM model based on MRI radiomics exhibits high efficacy in the diagnosis of cognitive dysfunction and evaluation of its severity among patients with T2DM.